Liquan Huang1, Guiyuan Chen1, Bo Hu2, Shuxia Liang3, Wenya Chu4, Li Chen5. 1. Nursing Faculty, School of Medicine, Jinhua Polytechnic Jinhua 321007, Zhejiang, P. R. China. 2. Department of Obstetrics and Gynecology, Jinhua People's Hospital Jinhua 321000, Zhejiang, P. R. China. 3. Department of Outpatient, Jinhua Municipal Central Hospital Jinhua 321000, Zhejiang, P. R. China. 4. Department of Hematology, Jinhua Municipal Central Hospital Jinhua 321000, Zhejiang, P. R. China. 5. Midwifery Faculty, School of Medicine, Jinhua Polytechnic Jinhua 321007, Zhejiang, P. R. China.
Abstract
OBJECTIVE: Peripherally inserted central catheter (PICC) is being increasingly used in critical care settings. However, PICC is associated with various complications, particularly venous thrombosis. Our aim was to observe the effects of preventive application of low molecular weight heparin on venous thrombosis in a PICC model. METHODS: All rabbits were randomly divided into four groups: a control group, and low/medium/high concentration of low molecular weight heparin groups. All rabbits were injected prophylactically with normal saline or low molecular weight heparin once a day for 7 days. A PICC model was constructed. The pathologic changes of ear vein, anterior vena cava, and venous thrombosis were investigated using hematoxylin and eosin (H&E). Biochemical testing was performed including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Serum D-dimer (D2D) and fibrinogen (FG) levels were detected using Enzyme-linked immunosorbent assay (ELISA). RESULTS: X-ray results showed that the PICC model was successfully constructed. H&E results showed that preventive application of low molecular weight heparin significantly ameliorated the pathologic damage to ear vein and anterior vena cava in the PICC model. Furthermore, we found that preventive application of low molecular weight heparin inhibited venous thrombosis in the model by H&E stain. Moreover, it significantly reduced serum FG and D2D levels in PICC model. Biochemical testing results showed that PT, APTT, and TT were significantly elevated in the PICC model. CONCLUSION: Our findings revealed that preventive application of low molecular weight heparin significantly ameliorates venous thrombosis in a PICC model. IJCEP
OBJECTIVE: Peripherally inserted central catheter (PICC) is being increasingly used in critical care settings. However, PICC is associated with various complications, particularly venous thrombosis. Our aim was to observe the effects of preventive application of low molecular weight heparin on venous thrombosis in a PICC model. METHODS: All rabbits were randomly divided into four groups: a control group, and low/medium/high concentration of low molecular weight heparin groups. All rabbits were injected prophylactically with normal saline or low molecular weight heparin once a day for 7 days. A PICC model was constructed. The pathologic changes of ear vein, anterior vena cava, and venous thrombosis were investigated using hematoxylin and eosin (H&E). Biochemical testing was performed including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Serum D-dimer (D2D) and fibrinogen (FG) levels were detected using Enzyme-linked immunosorbent assay (ELISA). RESULTS: X-ray results showed that the PICC model was successfully constructed. H&E results showed that preventive application of low molecular weight heparin significantly ameliorated the pathologic damage to ear vein and anterior vena cava in the PICC model. Furthermore, we found that preventive application of low molecular weight heparin inhibited venous thrombosis in the model by H&E stain. Moreover, it significantly reduced serum FG and D2D levels in PICC model. Biochemical testing results showed that PT, APTT, and TT were significantly elevated in the PICC model. CONCLUSION: Our findings revealed that preventive application of low molecular weight heparin significantly ameliorates venous thrombosis in a PICC model. IJCEP
Authors: Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Andrea D'Alessio; Marina Marchetti; Carmen Julia Tartari; Laura Russo; Sara Cecchini; Kim W F M Lambregts; Daniela di Mauro; Anna Falanga Journal: Cancer Invest Date: 2017-07-10 Impact factor: 2.176
Authors: J M Ferro; M-G Bousser; P Canhão; J M Coutinho; I Crassard; F Dentali; M di Minno; A Maino; I Martinelli; F Masuhr; D Aguiar de Sousa; J Stam Journal: Eur J Neurol Date: 2017-08-20 Impact factor: 6.089
Authors: I Dotan; R Hershkoviz; F Karmeli; E Brazowski; Y Peled; D Rachmilewitz; Z Halpern Journal: Aliment Pharmacol Ther Date: 2001-10 Impact factor: 8.171
Authors: Vineet Chopra; Sarah Anand; Andy Hickner; Michael Buist; Mary Am Rogers; Sanjay Saint; Scott A Flanders Journal: Lancet Date: 2013-05-20 Impact factor: 79.321